AR093903A1 - Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad - Google Patents

Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad

Info

Publication number
AR093903A1
AR093903A1 ARP130104612A ARP130104612A AR093903A1 AR 093903 A1 AR093903 A1 AR 093903A1 AR P130104612 A ARP130104612 A AR P130104612A AR P130104612 A ARP130104612 A AR P130104612A AR 093903 A1 AR093903 A1 AR 093903A1
Authority
AR
Argentina
Prior art keywords
glucagon
glp
obesity
treatment
coagonists
Prior art date
Application number
ARP130104612A
Other languages
English (en)
Spanish (es)
Inventor
Fritsch-Fredin Maria
Jackson Ronald
Lofmark Rasmus
Metcalfe Jaqueline
Burmeister Nicole
Bentham Lambertus
Fairman David
Agoram Bilaji
Bednarek Maria
Antonsson Madeleine
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of AR093903A1 publication Critical patent/AR093903A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ARP130104612A 2012-12-11 2013-12-10 Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad AR093903A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261735823P 2012-12-11 2012-12-11

Publications (1)

Publication Number Publication Date
AR093903A1 true AR093903A1 (es) 2015-06-24

Family

ID=50588751

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104612A AR093903A1 (es) 2012-12-11 2013-12-10 Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad

Country Status (26)

Country Link
US (4) US9765130B2 (cg-RX-API-DMAC7.html)
EP (2) EP2931745B1 (cg-RX-API-DMAC7.html)
JP (1) JP6490011B2 (cg-RX-API-DMAC7.html)
KR (1) KR102080366B1 (cg-RX-API-DMAC7.html)
CN (2) CN104822699B (cg-RX-API-DMAC7.html)
AR (1) AR093903A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013356934C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015012238B1 (cg-RX-API-DMAC7.html)
CA (1) CA2893445C (cg-RX-API-DMAC7.html)
CY (2) CY1121114T1 (cg-RX-API-DMAC7.html)
DK (2) DK2931745T3 (cg-RX-API-DMAC7.html)
ES (2) ES2698329T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20220734T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039952T2 (cg-RX-API-DMAC7.html)
LT (2) LT3495380T (cg-RX-API-DMAC7.html)
MX (2) MX365458B (cg-RX-API-DMAC7.html)
PL (2) PL2931745T3 (cg-RX-API-DMAC7.html)
PT (2) PT3495380T (cg-RX-API-DMAC7.html)
RS (2) RS63305B1 (cg-RX-API-DMAC7.html)
RU (2) RU2018137842A (cg-RX-API-DMAC7.html)
SG (2) SG11201503230XA (cg-RX-API-DMAC7.html)
SI (2) SI3495380T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201800611T1 (cg-RX-API-DMAC7.html)
TR (1) TR201815172T4 (cg-RX-API-DMAC7.html)
TW (2) TWI617574B (cg-RX-API-DMAC7.html)
WO (1) WO2014091316A2 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CA2902352A1 (en) * 2013-03-14 2014-09-18 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN106519015B (zh) * 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN117106085A (zh) * 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
CN106938050B (zh) * 2015-12-29 2021-08-24 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
SG10202109721PA (en) * 2016-03-10 2021-10-28 Medimmune Ltd Glucagon and glp-1 co-agonists for the treatment of obesity
US20190388510A1 (en) * 2016-06-02 2019-12-26 Indiana University Research And Technology Corporation Glucagon-t3 conjugates
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽-1及其修饰物的应用
US11419918B2 (en) * 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物
SMT202200352T1 (it) 2018-04-05 2022-09-14 Sun Pharmaceutical Ind Ltd Analoghi del glp-1 innovativi
US12257287B2 (en) 2018-11-12 2025-03-25 Tianjin Institute Of Pharmaceutical Research Co., Ltd. Glucagon-derived peptide and use thereof
CA3139613A1 (en) 2019-05-21 2020-11-26 Medimmune Limited Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
MX2021015930A (es) 2019-07-01 2022-02-03 Medimmune Ltd Composiciones farmaceuticas para peptidos co-agonistas de glucagon y glp-1.
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
EP4069720A4 (en) * 2019-12-03 2023-12-27 MedImmune, LLC COMBINATION THERAPY WITH GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
TW202140061A (zh) 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療2型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及glp-1協同促效劑
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
CN120737188A (zh) 2020-04-24 2025-10-03 勃林格殷格翰国际有限公司 作为长效glp-1/升糖素受体激动剂以治疗脂肪肝疾病及脂肪肝炎的升糖素类似物
TW202313974A (zh) 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 用於治療肝病之組合療法
KR20240043778A (ko) 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽
US20240148833A1 (en) * 2022-11-03 2024-05-09 EFIL BioScience Inc. Composition comprising glp-1 receptor agonist and acat inhibitor
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法
EP4724472A2 (en) 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2025024788A1 (en) * 2023-07-27 2025-01-30 Biomedit, Llc Stabilized glp-1 peptides and dual agonist peptides against glp-1r and gipr and methods of use thereof
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
AU2024408289A1 (en) 2023-12-22 2026-08-06 Tangram Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
US20260091086A1 (en) 2024-05-20 2026-04-02 Medimmune Limited Polypeptide combinations and uses thereof
CN118787658B (zh) * 2024-06-14 2025-01-21 中国农业大学 一种胰高血糖素样肽-1受体特异性核酸适配体在代谢疾病干预中的应用
WO2026058194A1 (en) 2024-09-12 2026-03-19 Medimmune Limited Polypeptide dosage regimens
WO2026093970A1 (en) 2024-11-01 2026-05-07 Medimmune Limited Combination dosage regimens of amylin receptor agonists and glp-1 receptor agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30326A (en) * 1860-10-09 Steam-g-eneratob
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
CA2497794A1 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
CN1938334A (zh) * 2004-01-30 2007-03-28 瓦拉塔药品公司 Glp-1激动剂和胃泌素化合物的联合使用
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
CN1935846A (zh) * 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
WO2009058734A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
ES2661228T3 (es) * 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑

Also Published As

Publication number Publication date
PL3495380T3 (pl) 2022-08-01
US11230584B2 (en) 2022-01-25
WO2014091316A2 (en) 2014-06-19
EP3495380A1 (en) 2019-06-12
SG10201801159WA (en) 2018-03-28
HRP20220734T1 (hr) 2022-09-02
TWI617574B (zh) 2018-03-11
SMT201800611T1 (it) 2019-01-11
JP6490011B2 (ja) 2019-03-27
TW201829452A (zh) 2018-08-16
TW201427993A (zh) 2014-07-16
MX2015006568A (es) 2015-08-05
WO2014091316A3 (en) 2014-10-30
LT3495380T (lt) 2022-06-27
AU2017261505A1 (en) 2017-12-07
EP3495380B1 (en) 2022-03-30
BR112015012238B1 (pt) 2022-03-29
KR102080366B1 (ko) 2020-02-21
AU2017261505B2 (en) 2019-10-10
JP2016501256A (ja) 2016-01-18
CN109776670A (zh) 2019-05-21
AU2019272054A1 (en) 2020-01-02
US20220098265A1 (en) 2022-03-31
US20170342121A1 (en) 2017-11-30
BR112015012238A2 (cg-RX-API-DMAC7.html) 2017-08-15
MX365458B (es) 2019-06-04
RU2018137842A3 (cg-RX-API-DMAC7.html) 2022-04-01
TR201815172T4 (tr) 2018-11-21
MX2019006260A (es) 2019-08-14
PT3495380T (pt) 2022-06-28
HK1216179A1 (en) 2016-10-21
CA2893445A1 (en) 2014-06-19
SI2931745T1 (sl) 2018-11-30
CY1125302T1 (el) 2025-03-28
PL2931745T3 (pl) 2019-04-30
SMT202200266T1 (it) 2022-07-21
AU2013356934A1 (en) 2015-05-21
US9765130B2 (en) 2017-09-19
US20150307579A1 (en) 2015-10-29
ES2926713T3 (es) 2022-10-27
RU2018137842A (ru) 2018-12-13
RU2671088C2 (ru) 2018-10-29
EP2931745B1 (en) 2018-08-22
SG11201503230XA (en) 2015-06-29
RU2015127780A (ru) 2017-01-19
TWI674270B (zh) 2019-10-11
LT2931745T (lt) 2018-11-12
AU2013356934B2 (en) 2017-08-17
KR20150093167A (ko) 2015-08-17
CA2893445C (en) 2020-06-02
HRP20181678T1 (hr) 2019-03-08
MX388904B (es) 2025-03-20
PT2931745T (pt) 2018-11-29
ES2698329T3 (es) 2019-02-04
EP2931745A2 (en) 2015-10-21
AU2017261505C1 (en) 2020-07-30
RS57899B1 (sr) 2019-01-31
AU2013356934C1 (en) 2018-07-05
CY1121114T1 (el) 2019-12-11
DK3495380T3 (da) 2022-06-20
US20200115431A1 (en) 2020-04-16
CN104822699A (zh) 2015-08-05
RS63305B1 (sr) 2022-07-29
DK2931745T3 (en) 2018-12-10
SI3495380T1 (sl) 2022-08-31
CN104822699B (zh) 2019-03-01
HUE039952T2 (hu) 2019-02-28
US10556939B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
MX2019006260A (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad.
JOP20200119A1 (ar) مركبات مساعد مشترك من gip وglp-1
AR086998A1 (es) Coagonistas del receptor de glucagon/glp-1
PE20240686A1 (es) Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
GT201700224A (es) Proteína de unión a rgma y su uso
AR088737A1 (es) Familia de toxinas inhibidoras de insectos activa contra insectos hemipteros y/o lepidopteros
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
AR092076A1 (es) Proteinas homodimericas
HK1220383A1 (zh) 用於治疗肥胖症的聚乙二醇化的胰高血糖素和glp-1共激动剂
HK1256909A1 (zh) Glp-1和其在用於治疗代谢疾病的组合物中的用途
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
NZ726623A (en) Improved peptide pharmaceuticals for insulin resistance
AR099068A1 (es) Anticuerpo anti-netrina-1
MX2016007407A (es) Peptidos resistentes a proteasa.
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)
WO2013006692A3 (en) Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
EP2552462A4 (en) CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS
CO2019006443A2 (es) Peptido para tratar degeneracion macular relacionada con la edad
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
JP2017517561A5 (cg-RX-API-DMAC7.html)
AR098615A1 (es) Péptido para el tratamiento de hipoglicemia severa

Legal Events

Date Code Title Description
FB Suspension of granting procedure